1620146-75-9

Upstream product

• 100-44-7 benzyl chloride 
• 74-88-4 methyl iodide 
• 52085-14-0 4-benzoxy-salicylaldehyde 
• 552845-88-2 5-bromo-4-hydroxy-2-methoxy-benzaldehyde 
• 620-05-3 iodomethylbenzene 
• 1227484-24-3 5-bromo-2-methoxy-4-(methoxymethoxy)benzaldehyde 
• 1227484-18-5 5-bromo-2-hydroxy-4-(methoxymethoxy)benzaldehyde 
• 116096-90-3 5-bromo-2,4-dihydroxy-benzaldehyde 
• 95-01-2 2,4-Dihydroxybenzaldehyde 

Downstream Products

• 1620146-46-4 (Z)-5-(5-bromo-4-benzyloxy-2-methoxybenzylidene)-3-methylthiazolidine-2,4-dione 
• 1620146-44-2 (Z)-5-(5-bromo-4-benzyloxy-2-methoxybenzylidene)thiazolidine-2,4-dione 
• 1625667-62-0 2-(4-(benzyloxy)-5-bromo-2-methoxybenzyl)benzo[b]thiophene 

Relevant academic research and scientific papers

5-FLUORO-C-(ARYL OR HETEROCYCLYL)-GLYCOSIDE DERIVATIVES USEFUL AS DUAL SGLT1 / SGLT2 MODULATORS

The present invention is directed to 5-fluoro-C-(aryl or hetercyclyl)-glycoside derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by SGLT activity, more particularly dual SGLT1/2 activity.

DUAL SGLT1/SGLT2 INHIBITORS

The present invention relates to compounds of Formula (I), or a form thereof, wherein A, R1, R2, R3, R4, and R5 are as defined herein, useful as dual SGLT1/SGLT2 inhibitors.

Design, synthesis and docking study of 5-(substituted benzylidene) thiazolidine-2,4-dione derivatives as inhibitors of protein tyrosine phosphatase 1B

A series of novel 5-(substituted benzylidene)thiazolidine-2,4-dione derivatives was designed, and synthesized based on our previous studies. Also their activities were evaluated as competitive inhibitors of protein tyrosine phosphatase 1B (PTP1B). Compounds 6d-6g, 7b, 7c, 7e, 7j, 7k, 7m, 14b and 14e-14f showed potent inhibitory effects against PTP1B, and compound 7e, the most potent among the series, had an IC50 of 4.6 μM. Also a Surflex-Dock docking model of 7e was studied. Compound 7e showed a negative binding energy of -7.35 kcal/mol and a high affinity to PTP1B residues (Gly220, Ala217, Arg221, Asp181, Ser216, Cys215, Phe182, Gln262 and Ile219) in the active sites, indicating that it may stabilize the open form and generate tighter binding to the catalytic sites of PTP1B.